Pyxis Oncology expands board to 7, appoints Dr. Jakob Dupont as director contingent on Apexigen merger

Pyxis Oncology, Inc.

Board size increased to seven members, effective upon closing of merger with Apexigen.
Dr. Jakob Dupont appointed as Class III director, term expiring at 2024 annual meeting.
Dr. Dupont executed voting agreement to support merger proposals; no other arrangements or family ties.
Appointment contingent on merger completion; Dr. Dupont eligible for non-employee director compensation.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jakob Dupont

Director

PYXS · Pyxis Oncology, Inc.

Filed: June 30, 2023, 7:59 PM ET

the Board also approved on a prospective basis the appointment of Jakob Dupont, M.D. as a director of the Company to fill the vacancy created by that action.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jakob Dupont was appointed as Director at Pyxis Oncology, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board also approved on a prospective basis the appointment of Jakob Dupont, M.D. as a director of the Company to fill the vacancy created by that action.

View on SEC.gov

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-031128

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.